Evidence method
Level · gp.fundamentals.debt_to_revenue
107.95% · OPTIONAL · NOT_ENOUGH_HISTORY
Indivior Pharmaceuticals, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
107.95% · OPTIONAL · NOT_ENOUGH_HISTORY
Level · gp.fundamentals.capex_revenue_ratio
5.63% · OPTIONAL · NOT_ENOUGH_HISTORY
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
52.32% · OPTIONAL · NOT_ENOUGH_HISTORY
Level · gp.fundamentals.inventory_revenue_ratio
49.34% · OPTIONAL · NOT_ENOUGH_HISTORY
Level · gp.fundamentals.gross_margin
82.78% · CORE · NOT_ENOUGH_HISTORY
Level · gp.fundamentals.operating_margin
23.84% · CORE · NOT_ENOUGH_HISTORY
Level · gp.fundamentals.sbc_revenue_ratio
2.65% · OPTIONAL · NOT_ENOUGH_HISTORY
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.